Senseonics Holdings, Inc. — Third Quarter 2026 Earnings Summary

Financial Performance:

• Reported third-quarter 2026 revenue of $19.6 million, a 140% increase year-over-year from $8.1 million in Q3 2025.
• U.S. revenue reached $16.8 million in Q3 2026, up 160% year-over-year from $6.4 million, while international revenue was $2.8 million, up 65% from $1.7 million.
• Gross profit for Q3 2026 was $12.1 million, representing a gross margin of approximately 62%, compared to $3.5 million (43% margin) in Q3 2025.
• Research and development expenses were $11.7 million in Q3 2026, up from $7.8 million in the prior year period.
• Selling, general, and administrative expenses totaled $32.3 million in Q3 2026, compared to $15.3 million in Q3 2025.
• Net loss for Q3 2026 was $32.7 million ($0.50 per share), compared to a net loss of $19.5 million ($0.43 per share) in Q3 2025.
• As of September 30, 2026, cash, cash equivalents, restricted cash, and short-term investments totaled $126.6 million.
• Carrying value of debt under the Hercules Capital facility was approximately $56.2 million, with $55.0 million in principal borrowings outstanding.

Guidance and Future Outlook:

• Raised full-year 2026 global net revenue guidance to $68 million–$70 million, up from the previous range of $62 million–$66 million, representing 93% to 98% year-over-year growth.
• Raised full-year 2026 gross margin guidance to more than 60%, up from the previous range of 58% to 61%.
• Expects revenue outside the United States to represent approximately 15% of full-year 2026 revenue.
• Outlook reflects continued momentum in U.S. Eversense 365 growth, planned direct-to-consumer marketing investment, and the ongoing rollout of Eversense 365 outside the United States.

Business Segments and Product Lines:

• U.S. active prescribers increased approximately 90% year-over-year in Q3 2026.
• The EON Care network grew to more than 100 inserters, who performed over 40% of third-quarter Eversense insertion procedures; the target goal is 120 inserters by year-end.
• Announced a strategic partnership with Beta Bionics to integrate Eversense 365 with the iLet® Bionic Pancreas automated insulin delivery system, with a commercial launch planned for Q4 2026.
• Initiated the first-in-human study for "Freedom," an investigational next-generation CGM system designed to communicate directly with a mobile device without an on-body component.
• Commercial operations for Eversense 365 are now fully in-house globally, with dedicated teams leading launches in European markets.

Market and Competitive Landscape:

• Eversense 365 is the world's first and only one-year CGM system, cleared in the U.S. and approved in Europe for patients aged 18 and older.
• The company is expanding pump compatibility and advancing a product pipeline designed to reduce device burden.
• The partnership with Beta Bionics aims to expand patient choice by pairing Eversense with another insulin delivery system.

Risks and Challenges:

• Forward-looking statements cite risks related to demand, adoption, reimbursement, sales mix, and costs affecting revenue and gross margins.
• Risks include uncertainties in clinical development, regulatory review, and successful commercialization of new technology, including Gemini and Freedom.
• Potential challenges involve the ability to expand commercial infrastructure, complete integrations with partners, and satisfy applicable requirements.
• Risks include uncertainties in insurer, regulatory, and administrative processes, as well as the effects of tariffs and the current economic and regulatory/political environment.

Management Commentary and Tone:

• CEO Tim Goodnow stated that 140% year-over-year revenue growth reflects progress in executing the commercial strategy and driving awareness for Eversense 365.
• Management expressed confidence that recent investments in commercial infrastructure are expanding patient access, supporting growth, and improving gross margins.
• Chief Commercial Officer Brian Hansen highlighted that multiple initiatives to expand awareness and access create opportunities to reach new patients and prescribers.
• Management noted that the EON Care network allows for extended direct-to-consumer and healthcare provider outreach into additional markets.

Other Key Points:

• This marks the third consecutive quarter of strong execution since bringing U.S. Eversense commercial operations in-house.
• The company is building on a successful partnership with Sequel and the integration between Eversense 365 and twiist™.
• Conference call details were provided for November 9, 2026, at 4:30 p.m. Eastern Time, with webcast and dial-in options available.
• The company maintains a focus on reducing device burden and offering greater convenience in everyday life for diabetes management.